- Genmab A/S (NASDAQ:GMAB) has announced that AbbVie Inc (NASDAQ:ABBV) will submit a conditional marketing authorization application with the European Medicines Agency for subcutaneous epcoritamab (DuoBody-CD3xCD20) for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), in 2H of 2022.
- Epcoritamab is an investigational bispecific antibody.
- Genmab recently announced that the company would submit a biologics license application (BLA) for epcoritamab with FDA for relapsed/refractory large B-cell lymphoma (LBCL), also in 2H of 2022.
- Related: AbbVie – Genmab Present Epcoritamab Data From Lymphoma Trial.
- The European submission is supported by results from the large b-cell lymphoma (LBCL) cohort of the pivotal EPCORE NHL-1 trial.
- Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies’ oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.
- Price Action: ABBV shares are down 1.13% at $151.86, and GMAB is up 1.64% at $34.87 during the market session on the last check Monday.
Natera Priced Follow-On Offering of ~11.4M Shares at $35/Share
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 11,430,000 shares of its common stock at a price to the public of $35.00 per share.
